Please
read the following information and select the appropriate link
at the bottom of the page to continue.

Release
Date: May
2002
Expiration Date: May
2004

Target
Audience
This activity has been designed to meet the educational
needs of pharmacists and registered nurses involved with the
management of patients with diabetes.

Goal
Statement
Provide pharmacists and nurses with information
on the importance of glycemic control and knowledge of a variety
of methods of insulin delivery so that they may guide patients
with diabetes in selecting the most suitable delivery method.

Educational
Objectives
Upon completion of this activity, participants
should be able to:

Describe
the importance of good glycemic control for patients with
diabetes

Describe
two insulin delivery systems currently in use in the United
States, other than vial and syringe delivery

Pharmacist
Continuing Education
The Postgraduate Institute for Medicine and Novo Nordisk Pharmaceuticals,
Inc. are approved by the American Council on Pharmaceutical
Education as providers of continuing pharmaceutical education.
The Postgraduate Institute for Medicine designates this continuing
education activity for 1 contact hour (0.10 CEUs). Universal
Program Number: 890-360/999-02-045-H01

A
statement of credit will be issued only upon receipt of a successfully
completed post-test (70% or better) and activity evaluation
form.

Nursing
Continuing Education
This educational activity for 1.2 contact hours is provided
by Postgraduate Institute for Medicine. Postgraduate Institute
for Medicine is approved as a provider of continuing education
in nursing by the Colorado Nurses' Association, which is accredited
as an approver of continuing education in nursing by the American
Nurses Credentialing Center's Commission on Accreditation.

The Postgraduate Institute for Medicine is approved by the California
Board of Registered Nursing, Provider Number 13485, for 1.2
contact hours.

Faculty
Disclosure Statements
Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or
apparent commercial financial affiliations related to the content
of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse impact
on faculty presentations; they are simply noted here to fully
inform participants.
Angela Bacque, RPh, MPA, CDE, disclosed having no relationships
with commercial entities related to the information presented
in the publication.
Lynn S. Weiss, RN, MS, CDE, disclosed having no relationships
with commercial entities related to the information presented
in the publication.

Disclosure
of Unlabeled Use
This educational activity may contain discussion of published
and/or investigational uses of agents that are not indicated
by the FDA. The Postgraduate Institute for Medicine, Novo Nordisk
Pharmaceuticals, Inc., and Pharmaceutical Information Associates
do not recommend the use of any agent outside of the labeled
indications. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications
and warnings.

Disclaimer
Participants have an implied responsibility to use the newly
acquired information to enhance patient outcomes and their own
professional development. The information presented in this
activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or
treatment discussed or suggested in this activity should not
be used by clinicians without evaluation of their patient's
conditions and possible contraindications or dangers in use,
review of any applicable manufacturer's product information,
and comparison with recommendations of other authorities.

Trademarks
NovoLog, Novolin, NovoPen3, NovoPen Junior, FlexPen, NovoPen
1.5, Innovo, PenFill, NovoFine, InnoLet, and Velosulin BR are
registered trademarks of Novo Nordisk A/S.Novolin Prefilled is a trademark of Novo Nordisk A/S.InTouch is a registered trademark of LifeScan, Inc.Humulin and Humalog are registered trademarks of Eli Lilly and Company.Animas R1000 is a registered trademark of Animas Corporation.H-TRONplus, Dahedi, D-TRON, and Disetronic Pen are trademarks of Disetronic Medical Systems, Inc.Lantus is a registered trademark of Aventis Pharmaceuticals.BD is a trademark of Becton Dickinson.Autopen is a registered trademark of Owen Mumford, Ltd.MiniMed 508 and Paradigm are registered trademarks of Medtronic MiniMed, Inc.InDuo is a trademark of Johnson & Johnson and Novo Nordisk A/S.

Fee
There is no fee to receive credits for this continuing education
activity.Click the appropriate profession to continue to the activity:

No part of this
program may be reproduced, stored in a retrieval system, or transmitted
in any form or by any means (electronic, electrostatic, magnetic tape,
mechanical, photocopying, recording, or otherwise) without permission
from Novo Nordisk Pharmaceuticals, Inc. Published by Health Answers
Inc., 1140 Welsh Road, Suite 100, North Wales, PA 19454